Latest News

Latest News

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Who Notices When a Clinical Model Drifts?

Who Notices When a Clinical Model Drifts?

Most clinical prediction tools get one big exam. Someone pulls a retrospective cohort, runs the numbers, shows a committee a curve, and the tool goes live. After that the exam rarely gets repeated, so model drift can go unnoticed. The emergency department keeps...

read more
UK Lab Space in 2026: Record Vacancy, Regional Squeeze

UK Lab Space in 2026: Record Vacancy, Regional Squeeze

UK lab space demand reached a record in 2026. So did UK lab space vacancy. CoStar data shows national laboratory vacancy hit a record 14.3% in the second quarter of 2026. That is more than double the level of two years earlier. Yet some regional science parks say...

read more
When the AI Inside a Medical Device Belongs to Someone Else

When the AI Inside a Medical Device Belongs to Someone Else

Medical device manufacturers have long relied on third-party technology. Generative AI, however, presents new challenges for manufacturers of AI medical devices, who may have little influence over how the external model is developed. The technology may be outside of...

read more
Redrawing the Limits of “Undruggable” Proteins

Redrawing the Limits of “Undruggable” Proteins

For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...

read more
An AI Study Without Its Data Is Fiction

An AI Study Without Its Data Is Fiction

Why publish the data at all? My answer comes from my own work. We ran our study not with one AI agent but with several, and later it turned out that the numbers did not match. Without validated AI study data, data that the author answers for in front of the scientific...

read more
Weekly News Roundup | 19 October 2026

Weekly News Roundup | 19 October 2026

Life science news 19 October 2026: three licensing deals, three FDA approvals and two MHRA announcements. Gilead Sciences signed a T-cell engager deal worth up to $1.875bn with Vir Biotechnology. Roche licensed an ALK7 obesity candidate from Rona Therapeutics. The...

read more
Clinical Trial Results 16 October 2026

Clinical Trial Results 16 October 2026

The clinical trial results 16 October 2026 cover neuroendocrine tumours, bladder, head and neck cancers, pulmonary fibrosis and social anxiety. RayzeBio’s RYZ101 met its primary endpoint at interim analysis in gastroenteropancreatic neuroendocrine tumours. The FDA...

read more
Who Notices When a Clinical Model Drifts?

Who Notices When a Clinical Model Drifts?

Most clinical prediction tools get one big exam. Someone pulls a retrospective cohort, runs the numbers, shows a committee a curve, and the tool goes live. After that the exam rarely gets repeated, so model drift can go unnoticed. The emergency department keeps...

read more
UK Lab Space in 2026: Record Vacancy, Regional Squeeze

UK Lab Space in 2026: Record Vacancy, Regional Squeeze

UK lab space demand reached a record in 2026. So did UK lab space vacancy. CoStar data shows national laboratory vacancy hit a record 14.3% in the second quarter of 2026. That is more than double the level of two years earlier. Yet some regional science parks say...

read more
When the AI Inside a Medical Device Belongs to Someone Else

When the AI Inside a Medical Device Belongs to Someone Else

Medical device manufacturers have long relied on third-party technology. Generative AI, however, presents new challenges for manufacturers of AI medical devices, who may have little influence over how the external model is developed. The technology may be outside of...

read more
Redrawing the Limits of “Undruggable” Proteins

Redrawing the Limits of “Undruggable” Proteins

For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...

read more
An AI Study Without Its Data Is Fiction

An AI Study Without Its Data Is Fiction

Why publish the data at all? My answer comes from my own work. We ran our study not with one AI agent but with several, and later it turned out that the numbers did not match. Without validated AI study data, data that the author answers for in front of the scientific...

read more
Weekly News Roundup | 19 October 2026

Weekly News Roundup | 19 October 2026

Life science news 19 October 2026: three licensing deals, three FDA approvals and two MHRA announcements. Gilead Sciences signed a T-cell engager deal worth up to $1.875bn with Vir Biotechnology. Roche licensed an ALK7 obesity candidate from Rona Therapeutics. The...

read more
Clinical Trial Results 16 October 2026

Clinical Trial Results 16 October 2026

The clinical trial results 16 October 2026 cover neuroendocrine tumours, bladder, head and neck cancers, pulmonary fibrosis and social anxiety. RayzeBio’s RYZ101 met its primary endpoint at interim analysis in gastroenteropancreatic neuroendocrine tumours. The FDA...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Bispecific T-Cell Engagers in Refractory Autoimmune Disease

Bispecific T-Cell Engagers in Refractory Autoimmune Disease

Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...

read more
Medicine Does Not Run on Blood Alone

Medicine Does Not Run on Blood Alone

Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...

read more

Further News

Weekly News Roundup | 2 November 2026

Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

ESMO 2026: The Five Results That Could Change Cancer Treatment

ESMO 2026 closed in Madrid on 27 October after five days of practice-shaping data. The most closely watched results came in three Presidential Symposia, which carried twelve late-breaking phase 3 trials. Five of them stand out for their potential to change how...

What Are You Signing When the AI Wrote the Note?

Anyone who has finished an emergency shift knows the chart stack. The department is still loud, the next team has the board, and a column of unsigned notes waits on the workstation. You read each one, fix what's wrong, and sign. That signature has always meant...

Peptide Compounding Explained: What the HHS Six-Peptide Policy Allows

Peptide compounding in the United States has entered a new phase. The Department of Health and Human Services (HHS) will not act against compounders of six unapproved peptides, within strict conditions. The peptides are BPC-157, Epitalon, KPV, MOTS-c, Semax and...

Clinical Trial Results 30 October 2026

Clinical trial results 30 October 2026: head and neck cancer, small cell lung cancer, type 2 diabetes and breast cancer. Genmab’s petosemtamab plus pembrolizumab met both co-primary endpoints in first-line PD-L1-positive head and neck cancer. Amgen’s tarlatamab plus...

Retatrutide vs Ozempic: How Do They Compare in Diabetes?

Retatrutide vs Ozempic now has a head-to-head answer in type 2 diabetes. In an 80-week phase 3 trial, retatrutide lowered A1C by 2.2 percentage points, against 1.8 for Ozempic 2 mg. Body weight fell by 19.5 to 20.9 per cent on retatrutide and 9.4 per cent on Ozempic....

Weight Is Not Composition: What Surgeons See After GLP-1 Weight Loss

The GLP-1 era has given clinicians something they have wanted for decades: medications that produce weight loss approaching what was once possible only with surgery. Semaglutide and tirzepatide routinely deliver reductions of 15% to 20% of body weight in trials, and...

Ferring Gameto Acquisition: What Does Ferring Get From the Deal?

The Ferring Gameto acquisition is worth up to $1.3825 billion with milestones. What Ferring gets, Fertilo’s phase 3 status and what to watch.

    What the Next Generation of GLP-1s Means for Pharmacists and Patients

    GLP-1 receptor agonists (GLP-1 RAs) have reshaped the treatment of type 2 diabetes and obesity. But the next phase of GLP-1 therapy, and of incretin-based treatment more broadly, is likely to have implications that extend well beyond the approval of another...

    Del-Desiran Next Steps: Will Novartis Continue After HARBOR?

    Del-desiran next steps after the HARBOR miss: what Novartis has said, the USD 1.9bn impairment and what would settle the DM1 programme’s future.

      Interoperability Begins Where Data Exchange Ends

      Standards and APIs can move information. True healthcare interoperability requires the governance, trust and workflow design that make the information usable. Healthcare has spent years treating interoperability as a problem of moving data. National exchange has...

      Psychobiotics and Depression: Exploring the Gut–Brain Connection

      Depression care continues to evolve as researchers explore why people respond differently to treatment. One area drawing attention is the relationship between the gut microbiome and the brain. Could psychobiotics, which target this connection, offer additional support...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.